Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: A multicenter case-matched study

Annals of Surgical Oncology

Volumn 20, Issue 11, 2013, Pages 3603-3609

  Barbier, Louise ^a,d   Fuks, David ^a   Pessaux, Patrick ^b   Muscari, Fabrice ^c   Le Treut, Yves Patrice ^d   Faivre, Sandrine ^a   Belghiti, Jacques ^a  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c CHU RANGUEIL   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CISPLATIN; GEMCITABINE; SORAFENIB;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED GASTRIC EMPTYING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; MALE; MORBIDITY; MULTICENTER STUDY; OPERATION DURATION; OPERATIVE BLOOD LOSS; PATIENT SAFETY; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PROTHROMBIN TIME; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84883810194     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3029-z     Document Type: Article

References (31)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
3. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 2010;78:154-66.
4. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Targ Oncol. 2010;5:59-63.
5. Bathaix F, Marion D, Cuinet M, et al. Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach. Gastroenterol Clin Biol. 2010;34:314-8.
6. Vagefi PA, Hirose R. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer. 2010;41:217-20.
7. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol. 2010;15:242-55.
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-40.
9. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553-9.
10. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol. 2003;30:39-50.
11. Barbare JC, Boige V, Boudjema K, et al. Carcinome hépatocellulaire (cancer primitif du foie). In: Thésaurus national de cancérologie digestive; 2011. http://www.snfge.com/data/ModuleDocument/publication/5/pdf/ TNCD-chapitre-7.pdf. Accessed 25 May 2013.
12. Shi M, Guo RP, Lin XJ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245:36-43.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
14. Balzan S, Belghiti J, Farges O, et al. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:828-9.
15. Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int. 2011;31:740-3.
16. Williet N, Dubreuil O, Boussaha T, et al. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol. 2011;17:2255-8.
17. Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011;2011:791013.
18. Feng YX, Wang T, Deng YZ, et al. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 2011;53:483-92.
19. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol. 2010;28:1502-7.
20. Hora C, Romanque P, Dufour JF. Effect of sorafenib on murine liver regeneration. Hepatology. 2011;53:577-86.
21. Kurniali PC, O'Gara K, Wang X, et al. The effects of sorafenib on liver regeneration in a model of partial hepatectomy. J Surg Res. 2012;178:242-7.
22. Moore M, Hirte HW, Siu L, et al. Study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005;16:1688-94.
23. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. 2009;49:1245-56.
24. Coriat R, Gouya H, Mir O, et al. Reversible decrease of portal venous flow in cirrhotic patients: a positive side-effect of sorafenib. PLoS One. 2011;6:e16978.
25. Yau T, Tao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270-9.
26. Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxyprothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:251-8.
27. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147-56.
28. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9.
29. Ronot M, Bouattour M, Wassermann J, et al. Early responders by new response criteria display long survival when treated with sorafenib for advanced hepatocellular carcinoma (HCC). Blinded central review using CHOI, EASL, and mRECIST. Presented at the International Liver Cancer Association (ILCA) meeting, 2012.
30. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009;9:208.
31. Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology. 2012;83:192-200.